ON24 to Participate in the 27th Annual Needham Growth Conference

SAN FRANCISCO--(BUSINESS WIRE)-- ON24 (NYSE: ONTF), a leading intelligent engagement platform for B2B sales and marketing, today announced participation in the following upcoming investor event:

• 27th Annual Needham Growth Conference
  January 14th, 2025
  Presentation at 4:30pm ET

A live webcast and replay of the presentation will be featured on the Company’s investor relations website at investors.on24.com.

About ON24

ON24 is on a mission to help businesses bring their go-to-market strategy into the AI era and drive cost-effective revenue growth. Through its leading intelligent engagement platform, ON24 enables customers to combine best-in-class experiences with personalization and content, to capture and act on connected insights at scale.

ON24 provides industry-leading companies, including 4 of the 5 largest global software companies, 3 of the 5 top global asset management firms, 3 of the 5 largest global healthcare companies and 3 of the 5 largest global industrial companies, with a valuable source of first-party data to drive sales and marketing innovation, improve efficiency and increase business results. Headquartered in San Francisco, ON24 has offices globally in North America, EMEA and APAC. For more information, visit www.ON24.com.

© 2025 ON24, Inc. All rights reserved. ON24 and the ON24 logo are trademarks owned by ON24, Inc., and are registered in the United States Patent and Trademark Office and in other countries

View source version on businesswire.com: https://www.businesswire.com/news/home/20250107671699/en/

Media:
Gabriella Kose
[email protected]

Investor:
Irmina Blaszczyk, The Blueshirt Group for ON24
[email protected]

Source: ON24, Inc.

You May Also Be Interested In

• KBRA Releases Research – AI Credit: Off to the Races—AI Infrastructure Commitments Are Reshaping the Credit Profiles of the AI-7 Companies
• Gameday Hospitality Celebrates 10th Football Season with Major Expansion & More Than 350 Events Nationwide
• A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity